Oncolytic virotherapy for pediatric malignancies: future prospects

Area of Science:

• Oncology
• Virology
• Pediatric Medicine

Background:

• Pediatric solid tumors are a significant health issue, causing numerous deaths and lifelong disabilities in survivors due to treatment toxicity.
• Current treatment regimens for pediatric solid tumors are often multimodal and associated with severe side effects.

Purpose of the Study:

• To review the current landscape of oncolytic virotherapy for pediatric solid tumors.
• To discuss the mechanisms, preclinical data, and clinical trial progress of four specific oncolytic viruses.

Main Methods:

• Review of existing literature on oncolytic viruses in pediatric preclinical studies.
• Analysis of data from past and ongoing pediatric clinical trials involving oncolytic viruses.
• Discussion of the mechanisms of action for herpes simplex virus-1, Seneca Valley virus, reovirus, and vaccinia virus.

Main Results:

• Four oncolytic viruses (herpes simplex virus-1, Seneca Valley virus, reovirus, vaccinia virus) have advanced to pediatric clinical trials.
• Preclinical studies demonstrate the potential of these viruses to selectively infect and kill tumor cells while sparing normal tissues.
• Ongoing clinical trials are evaluating the safety and efficacy of these viral therapeutics in children.

Conclusions:

• Oncolytic virotherapy represents a promising, targeted treatment strategy for pediatric solid tumors.
• Further research and clinical trials are essential to optimize the use of these novel viral therapeutics in pediatric oncology.
• The development of oncolytic viruses may lead to improved outcomes and reduced long-term disabilities for pediatric cancer survivors.